EP2509424A4 - Novel oxadiazole compounds - Google Patents
Novel oxadiazole compoundsInfo
- Publication number
- EP2509424A4 EP2509424A4 EP10836346.6A EP10836346A EP2509424A4 EP 2509424 A4 EP2509424 A4 EP 2509424A4 EP 10836346 A EP10836346 A EP 10836346A EP 2509424 A4 EP2509424 A4 EP 2509424A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- oxadiazole compounds
- novel oxadiazole
- novel
- compounds
- oxadiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000004866 oxadiazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26767909P | 2009-12-08 | 2009-12-08 | |
| PCT/US2010/046424 WO2011071570A1 (en) | 2009-12-08 | 2010-08-24 | Novel oxadiazole compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2509424A1 EP2509424A1 (en) | 2012-10-17 |
| EP2509424A4 true EP2509424A4 (en) | 2013-09-04 |
Family
ID=44145850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10836346.6A Withdrawn EP2509424A4 (en) | 2009-12-08 | 2010-08-24 | Novel oxadiazole compounds |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2509424A4 (en) |
| JP (1) | JP2013512951A (en) |
| CN (1) | CN102762102A (en) |
| AR (1) | AR077908A1 (en) |
| CA (1) | CA2783851A1 (en) |
| MX (1) | MX2012006667A (en) |
| TW (1) | TW201120016A (en) |
| UY (1) | UY32853A (en) |
| WO (1) | WO2011071570A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI577285B (en) | 2007-08-13 | 2017-04-11 | 孟山都科技有限責任公司 | Compounds and methods for controlling plant parasitic nematodes and seeds coated the compounds |
| WO2013036530A1 (en) | 2011-09-08 | 2013-03-14 | Allergan, Inc. | 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators |
| HUE035154T2 (en) | 2013-03-15 | 2018-05-02 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| US9828351B2 (en) * | 2014-06-26 | 2017-11-28 | Monash University | Enzyme interacting agents |
| US12209072B2 (en) | 2018-09-18 | 2025-01-28 | Bristol-Myers Squibb Company | Cyclopentyl acids as LPA antagonists |
| EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| CN112702998A (en) * | 2018-09-18 | 2021-04-23 | 百时美施贵宝公司 | Cycloheptanoic acids as LPA antagonists |
| CN109369620B (en) * | 2018-12-22 | 2020-04-14 | 山东大学 | Pyridine compound and its preparation method and anti-gastric cancer application |
| CN109776443B (en) * | 2019-03-25 | 2022-09-27 | 上海万巷制药有限公司 | Oxadiazole compound with antioxidant effect and preparation method thereof |
| WO2021099518A1 (en) | 2019-11-19 | 2021-05-27 | Modag Gmbh | Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein |
| UY38964A (en) | 2019-11-25 | 2021-06-30 | Novartis Ag | DERIVATIVES OF 1,2,4-OXADIAZOLE AS AGONISTS OF THE X LIVER RECEPTOR, THEIR USES AND RELATED METHODS CROSS REFERENCE TO RELATED APPLICATIONS |
| CN115260173B (en) * | 2021-04-30 | 2024-08-30 | 厦门宝太生物科技股份有限公司 | Cyclopentanoindole branched acid derivative and preparation method and application thereof |
| CN113662938B (en) * | 2021-09-26 | 2022-08-16 | 广西科技大学 | Application of amine derivative in preparation of anti-tumor pharmaceutical composition |
| US20250066341A1 (en) * | 2021-12-23 | 2025-02-27 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| WO2024151993A1 (en) * | 2023-01-13 | 2024-07-18 | Oppilan Pharma Limited | Preparation of an s1p receptor modulator |
| CN116444454B (en) * | 2023-06-16 | 2023-09-12 | 中国医学科学院医药生物技术研究所 | N-hydroxyamidine derivatives, preparation methods and applications, tumor immunotherapy drugs |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007080542A1 (en) * | 2006-01-11 | 2007-07-19 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives as s1p1/edg1 receptor agonists |
| WO2008029370A1 (en) * | 2006-09-08 | 2008-03-13 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
| WO2009109904A1 (en) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| WO2010148650A1 (en) * | 2009-06-26 | 2010-12-29 | Glaxo Group Limited | 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2258700A1 (en) * | 2006-05-09 | 2010-12-08 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| JP2010513283A (en) * | 2006-12-15 | 2010-04-30 | アボット・ラボラトリーズ | Novel oxadiazole compounds |
-
2010
- 2010-08-20 TW TW099128025A patent/TW201120016A/en unknown
- 2010-08-23 AR ARP100103076A patent/AR077908A1/en unknown
- 2010-08-23 UY UY0001032853A patent/UY32853A/en not_active Application Discontinuation
- 2010-08-24 EP EP10836346.6A patent/EP2509424A4/en not_active Withdrawn
- 2010-08-24 MX MX2012006667A patent/MX2012006667A/en not_active Application Discontinuation
- 2010-08-24 CA CA2783851A patent/CA2783851A1/en not_active Abandoned
- 2010-08-24 WO PCT/US2010/046424 patent/WO2011071570A1/en not_active Ceased
- 2010-08-24 CN CN2010800633803A patent/CN102762102A/en active Pending
- 2010-08-24 JP JP2012543093A patent/JP2013512951A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007080542A1 (en) * | 2006-01-11 | 2007-07-19 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives as s1p1/edg1 receptor agonists |
| WO2008029370A1 (en) * | 2006-09-08 | 2008-03-13 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
| WO2009109904A1 (en) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| WO2010148650A1 (en) * | 2009-06-26 | 2010-12-29 | Glaxo Group Limited | 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2011071570A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201120016A (en) | 2011-06-16 |
| AR077908A1 (en) | 2011-09-28 |
| CA2783851A1 (en) | 2011-06-16 |
| EP2509424A1 (en) | 2012-10-17 |
| MX2012006667A (en) | 2012-10-15 |
| UY32853A (en) | 2011-06-30 |
| CN102762102A (en) | 2012-10-31 |
| JP2013512951A (en) | 2013-04-18 |
| WO2011071570A1 (en) | 2011-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0919423D0 (en) | Novel compounds | |
| EP2483254A4 (en) | Novel compounds | |
| GB0905955D0 (en) | Novel compounds | |
| EP2509424A4 (en) | Novel oxadiazole compounds | |
| EP2512242A4 (en) | Novel compounds | |
| GB0910674D0 (en) | Novel compounds | |
| GB0910691D0 (en) | Novel compounds | |
| GB0911130D0 (en) | Novel compounds | |
| GB0910689D0 (en) | Novel compounds | |
| GB0910009D0 (en) | Novel compounds | |
| GB0910667D0 (en) | Novel compounds | |
| GB0910688D0 (en) | Novel compounds | |
| GB0912072D0 (en) | Novel compounds | |
| GB0902727D0 (en) | Novel compounds | |
| GB0907104D0 (en) | Novel compounds | |
| GB0907105D0 (en) | Novel compounds | |
| GB0907106D0 (en) | Novel compounds | |
| GB0910483D0 (en) | Novel compounds | |
| GB0906577D0 (en) | Novel compounds | |
| GB0917977D0 (en) | Novel compounds | |
| GB0912470D0 (en) | Novel compounds | |
| GB0907107D0 (en) | Novel compounds | |
| GB0907113D0 (en) | Novel compounds | |
| GB0912383D0 (en) | Novel compounds | |
| GB0906571D0 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20120703 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME RS |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20130802 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 487/04 20060101ALI20130729BHEP Ipc: A61K 31/41 20060101ALI20130729BHEP Ipc: C07D 471/04 20060101ALI20130729BHEP Ipc: A01N 43/82 20060101AFI20130729BHEP Ipc: C07D 413/12 20060101ALI20130729BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20140301 |